SAPIEN M3 Transcatheter Mitral Valve Replacement System
Edwards Lifesciences, LLC · Decision date Dec 22, 2025
What did the FDA approve?
FDA records P250019 as an original PMA application. The recorded decision is approval, dated Dec 22, 2025.
FDA approval order statement
Approval for the SAPIEN M3 transcatheter mitral valve replacement system. This device is indicated for the treatment of symptomatic moderate-to-severe or severe mitral regurgitation (MR) in patients who are deemed unsuitable for surgery or transcatheter edge-to-edge repair (TEER) therapy by a multidisciplinary heart team. It is also indicated for the treatment of symptomatic mitral valve dysfunction (moderate-to-severe or severe MR, severe mitral stenosis (MS), or moderate MR with moderate MS) associated with mitral annular calcification (MAC) in patients who are deemed unsuitable for surgery or TEER therapy by a multidisciplinary heart team.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Dec 22, 2025
Regulatory record facts
- Identifier
- P250019
- Regulatory pathway
- Premarket approval application
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NPU
- Decision code
- APPR
- Decision date
- Dec 22, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, mitral valve, percutaneously delivered.
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NPU
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250019 received
Application receipt date recorded by FDA.
P250019 · FDA decision
APPR
P250019/S001 · Related supplement
SAPIEN M3 Transcatheter Mitral Valve Replacement System
P250019/S002 · Related supplement
Edwards SAPIEN M3 Transcatheter Heart Valve (sizes 20mm, 23mm, 26mm, 29mm)
P250019/S003 · Related supplement
SAPIEN M3 Transcatheter Mitral Valve Replacement System
P250019/S005 · Related supplement
SAPIEN M3 Transcatheter Heart Valve (9880TFX29M)
P250019/S006 · Related supplement
Edwards SAPIEN M3 Dock (988DDS); Edwards 23F Guide Sheath (9880GS); Edwards SAPIEN M3 Crimper (9880CR); Edwards Commande
Timeline entries are records held by MedtechLedger for P250019. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250019
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Edwards Lifesciences, LLC | PMA supplement | Feb 19, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Mar 11, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Apr 16, 2026 | FDA | |
SAPIEN M3 Transcatheter Heart Valve (9880TFX29M)P250019/S005 | Edwards Lifesciences, LLC | PMA supplement | Jul 28, 2026 | FDA |
| Edwards Lifesciences, LLC | PMA supplement | Jul 29, 2026 | FDA |
Explore the linked device profile
Other records with product code NPU
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Tendyne Transcatheter Mitral Valve SystemP240042/S004 | ABBOTT MEDICAL | PMA supplement | Aug 31, 2026 | FDA |
Tendyne Transcatheter Mitral Valve SystemP240042/S003 | ABBOTT MEDICAL | PMA supplement | Aug 7, 2026 | FDA |
Tendyne Transcatheter Mitral Valve SystemP240042/S002 | ABBOTT MEDICAL | PMA supplement | Oct 4, 2025 | FDA |
Tendyne Transcatheter Mitral ValveP240042/S001 | ABBOTT MEDICAL | PMA supplement | Jul 29, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Edwards Lifesciences, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- One Edwards Way, Irvine, CA, 92614
Sources and methodology
- Original FDA record: P250019
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
